When tumors were grouped by TNM stage, NSCLC patients with late-stage disease (stage III + IV) showed higher expression of DDX39B than those with early-stage disease (stage I + II) (Fig. 1g). This evidence concerns the gene DDX39B and non-small cell lung carcinoma.